capital · May 18, 2026
Satellos Bioscience Advances BASECAMP Clinical Study in Q1 2026
Share the canonical public link.
Satellos Bioscience reported first-quarter 2026 financial results on May 15, 2026, noting progress in its BASECAMP studies for Duchenne muscular dystrophy. Eleven clinical trial sites for BASECAMP are currently active with remaining sites planned for activation throughout Q2 2026. The company raised $57 million in February 2026, providing cash runway through 2027 with $69.9 million available as of March 31, 2026. Satellos uplisted to Nasdaq during the period.
Spend governor blocked model creation: provider_circuit_open (lane=dev, provider=together)